Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic

Scand J Gastroenterol. 2021 May;56(5):545-551. doi: 10.1080/00365521.2021.1901308. Epub 2021 Mar 26.

Abstract

Background and aims: Patients with inflammatory bowel diseases (IBD) have experienced changes to the routine management because of the SARS-CoV-2 pandemic. The aim of this study was to examine patients with IBD's adherence to the restrictions imposed by society and the hospital, worries and concerns regarding medical treatment and clinical follow-up under the pandemic.

Methods: IBD patients (≥18 years) at the outpatient clinic at Oslo University Hospital were included and answered a self-report questionnaire including concerns regarding their disease, medical therapy and follow-up during SARS-CoV-2 pandemic.

Results: In total, 522 IBD patients were included, 317 Crohn's disease, 205 ulcerative colitis, 386 patients <50 years. Eighteen percent were in obligatory quarantine, and more often patients <50 years compared to patients ≥50 years. Five patients tested positive to SARS- CoV-2. A higher proportion <50 years reported worries for their medical treatment and risk of COVID -19 disease compared to those ≥50 years. Forty percent avoided family, two-thirds avoided friends, and 4% cancelled their scheduled consultation at the hospital. The hospital changed physical consultation to telephone consultation for 15% of the patients. The preferred follow-up was physical consultation. A higher proportion of the patients <50 years preferred telephone consultation compared to those ≥50 years. Four out of five IBD patients were satisfied with the information about their IBD and COVID-19.

Conclusions: SARS-CoV-2 pandemic affects the daily lives for patients with IBD. It is important to develop evidence-base guidelines in follow-up and treatment, as well as patient information about COVID-19and IBD.

Keywords: COVID-19; Inflammatory bowel disease; SARS-CoV-2; health-care service; immunosuppressive drugs.

MeSH terms

  • Adult
  • Attitude to Health
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / epidemiology
  • Colitis, Ulcerative* / psychology
  • Communicable Disease Control / methods
  • Communicable Disease Control / statistics & numerical data
  • Continuity of Patient Care / standards
  • Crohn Disease* / drug therapy
  • Crohn Disease* / epidemiology
  • Crohn Disease* / psychology
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Norway / epidemiology
  • Patient Compliance* / psychology
  • Patient Compliance* / statistics & numerical data
  • Patient Preference*
  • Physical Distancing
  • Remote Consultation / statistics & numerical data
  • SARS-CoV-2
  • Self Report

Substances

  • Immunosuppressive Agents